Elmind Capital LP Acquires Shares of 475,750 Pharvaris N.V. $PHVS

Elmind Capital LP acquired a new stake in Pharvaris N.V. (NASDAQ:PHVS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 475,750 shares of the company’s stock, valued at approximately $13,202,000. Pharvaris comprises approximately 3.9% of Elmind Capital LP’s portfolio, making the stock its 10th biggest position.

Other hedge funds also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in Pharvaris in the 4th quarter valued at $35,000. Barclays PLC bought a new position in Pharvaris in the 4th quarter valued at $77,000. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris in the 3rd quarter valued at $75,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris in the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. grew its position in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter.

Insider Buying and Selling at Pharvaris

In other news, Director Robert Glassman sold 10,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $29.82, for a total transaction of $298,200.00. Following the transaction, the director owned 10,500 shares of the company’s stock, valued at approximately $313,110. This represents a 48.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total value of $881,402.40. Following the transaction, the director directly owned 355,167 shares in the company, valued at $10,768,663.44. The trade was a 7.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 214,909 shares of company stock worth $6,421,745. Insiders own 11.84% of the company’s stock.

Pharvaris Trading Up 6.2%

PHVS opened at $33.41 on Thursday. Pharvaris N.V. has a 12-month low of $16.00 and a 12-month high of $33.50. The business’s fifty day simple moving average is $29.81 and its 200-day simple moving average is $27.67. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -10.51 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, equities research analysts predict that Pharvaris N.V. will post -3.22 EPS for the current year.

Wall Street Analysts Forecast Growth

PHVS has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a research report on Tuesday. UBS Group set a $74.00 price objective on Pharvaris in a research report on Wednesday, May 13th. Royal Bank Of Canada cut their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Citizens Jmp cut their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.